Literature DB >> 28551682

Surgical Outcomes of Non-small Cell Lung Cancer in Patients with a History of Pancreaticobiliary Cancer.

Tetsuzo Tagawa1,2, Kensaku Ito3, Kengo Fukuzawa4, Tatsuro Okamoto2, Atsuro Fujinaga4, Takahide Kawasaki4, Takashi Masuda4, Kentaro Iwaki4, Takahiro Terashi4, Masahiro Okamoto4, Akio Shiromizu4, Akira Motohiro3, Yoshihiko Maehara2.   

Abstract

AIM: To determine the efficacy of surgery for non-small cell lung cancer in patients who had previously undergone surgery for pancreaticobiliary cancer. PATIENTS AND METHODS: Seven patients who underwent pulmonary resection for primary lung cancer after curative surgery for pancreaticobiliary cancer at our Institution from 2006 to 2016 were retrospectively evaluated.
RESULTS: Five patients had metachronous and two patients had synchronous cancer of pancreaticobiliary and lung origin. The median time between surgeries for the two cancers was 35 months. All patients underwent complete resection of both cancers. The 5-year survival was 68.6% after pulmonary resection. Two patients had recurrence after lung surgery, with a mean recurrence-free interval of 6.5 months.
CONCLUSION: Surgery should be considered for lung cancer in patients who have undergone curative surgery for pancreaticobiliary cancer. Copyright
© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Lung cancer; double cancer; pancreaticobiliary cancer; surgery

Mesh:

Year:  2017        PMID: 28551682     DOI: 10.21873/anticanres.11698

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  2 in total

1.  Synchronous double primary malignancies of the pancreatic body and extrahepatic bile duct treated with pancreatoduodenectomy and splenic artery resection following neoadjuvant chemotherapy with gemcitabine plus nab-paclitaxel: a case report.

Authors:  Takahiro Murokawa; Takehiro Okabayashi; Kenta Sui; Motoyasu Tabuchi; Jun Iwata
Journal:  Surg Case Rep       Date:  2022-02-16

2.  Prognosis of Pancreatic Cancer Patients with Synchronous or Metachronous Malignancies from Other Organs Is Better than Those with Pancreatic Cancer Only.

Authors:  Su-Jin Shin; Hosub Park; You-Na Sung; Changhoon Yoo; Dae Wook Hwang; Jin-Hong Park; Kyu-Pyo Kim; Sang Soo Lee; Baek-Yeol Ryoo; Dong-Wan Seo; Song Cheol Kim; Seung-Mo Hong
Journal:  Cancer Res Treat       Date:  2017-12-20       Impact factor: 4.679

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.